Process Intensification And Other Ways To Adapt To Changing Needs

Biopharma manufacturers have more routes to productivity than ever, but choosing the right path is rarely simple. Mature modalities such as monoclonal antibodies still dominate the market, yet biosimilar competition, patent expirations, and demand shifts are pushing companies to rethink capacity, efficiency, and regional production strategies. At the same time, newer modalities—including mRNA, oligonucleotides, plasmids, and viral vectors—bring added process complexity, regulatory uncertainty, and the need for more flexible manufacturing platforms. Sustainability is also shaping vendor decisions, as companies increasingly expect suppliers to support measurable environmental commitments.

Explore how manufacturers can prioritize investments, adapt production strategies, and work with suppliers to improve productivity without losing flexibility in a fast-changing biologics landscape.